- Home
- SEZL vs VRDN Comparison
SEZL vs VRDN Comparison
Compare SEZL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- VRDN
- Stock Information
- Founded
- SEZL 2016
- VRDN 2006
- Country
- SEZL United States
- VRDN United States
- Employees
- SEZL N/A
- VRDN N/A
- Industry
- SEZL Diversified Financial Services
- VRDN Medical Specialities
- Sector
- SEZL Finance
- VRDN Health Care
- Exchange
- SEZL Nasdaq
- VRDN Nasdaq
- Market Cap
- SEZL 1.8B
- VRDN 1.6B
- IPO Year
- SEZL N/A
- VRDN N/A
- Fundamental
- Price
- SEZL $74.98
- VRDN $12.78
- Analyst Decision
- SEZL Strong Buy
- VRDN Buy
- Analyst Count
- SEZL 2
- VRDN 14
- Target Price
- SEZL $61.42
- VRDN $36.82
- AVG Volume (30 Days)
- SEZL 1.0M
- VRDN 912.1K
- Earning Date
- SEZL 05-07-2025
- VRDN 05-06-2025
- Dividend Yield
- SEZL N/A
- VRDN N/A
- EPS Growth
- SEZL 670.52
- VRDN N/A
- EPS
- SEZL 2.97
- VRDN N/A
- Revenue
- SEZL $329,060,890.00
- VRDN $302,000.00
- Revenue This Year
- SEZL $33.01
- VRDN N/A
- Revenue Next Year
- SEZL $16.24
- VRDN $20,553.29
- P/E Ratio
- SEZL $25.26
- VRDN N/A
- Revenue Growth
- SEZL 91.69
- VRDN 4.86
- 52 Week Low
- SEZL $10.46
- VRDN $9.90
- 52 Week High
- SEZL $81.83
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- SEZL 80.09
- VRDN 45.25
- Support Level
- SEZL $51.77
- VRDN $11.76
- Resistance Level
- SEZL $56.91
- VRDN $13.99
- Average True Range (ATR)
- SEZL 4.56
- VRDN 0.76
- MACD
- SEZL 2.10
- VRDN -0.00
- Stochastic Oscillator
- SEZL 84.51
- VRDN 35.79
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, primarily deriving revenue from payment processing platform in North America.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.